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Abstract
Background: Vigilant management of women with high-risk human papillomavirus (hrHPV) is necessary in cancer
screening programs. To this end, we evaluated the performance of S5 (targeting DNA methylation in HPV16, HPV18,
HPV31, HPV33, and human gene EPB41L3) to predict cervical intraepithelial neoplasia grade 2 or higher (CIN2+) in a
sample of hrHPV-infected women referred to colposcopy in the FRIDA Study, a large screening trial in Mexico. A
nested case-control sample with women referred to colposcopy either by atypical squamous cells of undetermined
significance or higher (ASCUS+) in cytology and/or positive for HPV types 16 or 18 was tested by S5. Seventy-nine
cases of CIN2+ were age-matched to 237 controls without a diagnosis of CIN2+ (<CIN2). DNA from exfoliated
cervical cells was bisulfite converted and PCR amplified for S5 targets, and methylation was quantified at specific
cytosines by pyrosequencing.
Results: The S5 classifier separated women with CIN2+ from <CIN2 with a highly significant area under the curve (AUC)
of 0.75 (95% CI 0.69–0.82), while AUC for CIN3+ was 0.81 (95% CI 0.74–0.89). To optimize sensitivity and specificity for
Mexico, an alternative S5 cutoff of 3.7 was implemented to account for overall higher methylation seen in our already
triaged women. All three invasive cancers were detected by methylation or HPV16/18 but none by cytology. Sensitivity of
S5 for CIN2+ was 62% (95% CI 50.4–72.7%), specificity was 73% (95% CI 66.9–78.5%), and adjusted PPV was 15.1% (95% CI
12.0–18.3%). In contrast, the crude sensitivity of HPV16/18 detection and cytology were 63.3% (95% CI 51.7–73.9%) and
57.0% (95% CI 45.3–68.1%) respectively; specificity was 29.1% (95% CI 23.4–35.3%) and 62.4% (95% CI 55.9–68.6%)
respectively, while adjusted PPV was 6.4% (95% CI 4.9–8.1%) and 10.5% (95% CI 8.0–13.1%), respectively. Methylation
testing could reduce colposcopy referrals by 30 to 50% with virtually no loss of sensitivity for CIN2+ and CIN3+.
Conclusions: S5 testing on hrHPV-positive women significantly increased diagnostic information compared to triage by
HPV16/18 plus cytology and appears to have clinical utility as an additional test to substantially lessen burdens on
colposcopy.
Trial registration: The FRIDA Study is registered in ClinicalTrials.gov, number NCT02510027.
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Background
Cervical cancer is the fourth leading cause of cancer-
related death in women worldwide, and developing re-
gions carry the greatest burden of this disease. In
Mexico, cervical cancer is ranked second as a cause of
death from malignancy in women [1–4]. The recognition
of persistent infection with high-risk human papilloma-
virus (hrHPV) as a major cause of cervical cancer [5–8]
has favored the development of new technologies for
hrHPV detection. The introduction of these tests as part
of primary screening for cervical cancer in various coun-
tries has greatly improved the detection of precancerous
lesions [9–12]. Some new testing procedures represent a
breakthrough in screening [9, 13, 14]; however, hrHPV
testing programs must incorporate triage before colpos-
copy referral because of the low specificity of hrHPV as-
says [15, 16]. The use of triage tests should enable the
relatively accurate identification of the small proportion
of hrHPV-positive women who need to go to colposcopy
given their increased risk of developing cancer. Triage
can reduce over-diagnosis and over-treatment of clinic-
ally non-relevant hrHPV infections [3, 17–19]. Various
types of triage tests have been proposed, including cy-
tology, p16/Ki67 immunocytochemistry, and HPV16/18
detection, but these methods still have important limita-
tions such as subjectivity of interpretation, low sensitiv-
ity, and low positive predictive value (PPV) [15, 16, 20].
DNA methylation, the enzymatic addition of a methyl
group to the carbon at position 5 of the cytosine ring in a
cytosine-phosphate-guanine (CpG) site, has been shown
to play an important role in the development of the car-
cinogenic process [21–25]. Many studies have found a
strong association between the methylation of host and
viral genome with the development of CIN2, CIN3, and
cancer [22, 23, 26–29]. Indeed, various quantitative com-
bination methylation assays are currently under evaluation
with the most common host genes being EPB41L3, MAL,
CADM, FAM19A4, and MIR124, as well as CpG sites in
the late regions of various HPV genomes [24, 30–35].
According to Clarke et al., methylation across all 12
carcinogenic HPV types is associated with precancer
(CIN3+), providing a better sensitivity than cytology as tri-
age test [36]. Other methylation marker panels designed
from methylation-specific real-time PCR assays are now
being validated with promising results [37], in particular,
the QIAsure methylation test, which is a multiplex real-
time methylation-specific PCR [38], and the GynTect
assay based on the detection of DNA methylation of hu-
man marker gene regions [37–39]. In our previous studies,
we have consistently found that methylation assays target-
ing the most carcinogenic HPV types help to distinguish
progressing infections and more severe lesions [22, 27,
32]. Indeed, we have found that the performance of
methylation to detect precancer improves as more HPV
viral types and human genes are added [30, 40]. In par-
ticular, the development of a methylation score—called
S5—combining DNA methylation levels of HPV16,
HPV18, HPV31, HPV33, and the human tumor suppres-
sor gene EPB41L3 has arisen as a promising biomarker
panel that can be used to triage hrHPV positive women.
At 90% sensitivity, S5 provided a specificity of 49% to
identify or predict the risk of a high-grade cervical lesion
in a UK colposcopy referral population [31]; in other
words, one half of the women sent for colposcopy
(regarded as an invasive examination) could have been
spared costs, a biopsy, and anxiety while being reassured
of highly sensitive detectability if they had a precancer.
The S5 classifier was developed in a colposcopy study [31]
and validated in screening studies in the UK and Canada
[28, 32]. The aim of our study was to extend validation of
the diagnostic performance of S5 and to find new applica-
tions in geographically and ethnically different women
undergoing triage in a large population-based HPV
screening cohort in Mexico. In this study, we explored the
utility of methylation testing in women with discrepant re-
sults between cervical cytology and HPV16/18 genotyping.
We give the term “already-triaged” to the women in our
study to avoid possible confusion over the role of an add-
itional methylation test.
Results
The 79 cases and 237 controls were composed mostly of
women aged between 30 and 49 (92.4%), with a median
age of 37 years. Figure 1 shows the consort diagram of
our nested case-control study: 29,759 cervical specimens
were tested for hrHPV (Cobas 4800). The grouped
prevalence of 13 types of hrHPV plus HPV66 (now
regarded as a low-risk HPV) was 10.8%. From 3228
hrHPV-positive women, 863 (26.7%) were positive on
initial triage (HPV16/18+ and/or ASCUS+); 672 of these
women were referred to colposcopy, and 561 attended
for colposcopy prior to our nested case-control study
cutoff date of July 2015; the colposcoped women were
the subjects of our methylation study.
There were no significant differences with respect to
demographics and lifestyle characteristics between cases
and controls (Additional file 1). Twenty-seven percent of
cases and 30% of controls began their sexual life before
the age of 16. The majority of cases and 51% of controls
reported having had one lifetime sexual partner. The
proportion of women who had used hormonal contra-
ceptives for more than 12months was the same (12.7%)
in both groups. Most women in both groups reported
not having used a condom during the last 12 months
(75% cases and 74% controls). 48.1% of cases and 36.7%
of controls had four or more pregnancies before FRIDA
enrollment. Overall, 90% of the study population had
never smoked (89.8% cases and 93.3% controls).
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Focusing on the HPV results, 60.8% of cases and 46.8%
of controls were HPV16-positive (p = 0.038). However,
only 6.3% of cases as compared to 26.6% of controls were
HPV18-positive (p = 0.000). With respect to other hrHPV
types, 24.1% of cases and 19.4% of controls were positive
for HPV31 (p = 0.422). Similarly, 6.3% of cases and 5.9% of
controls were HPV33-positive (p = 1.00). Fifty-five percent
of both cases and controls were positive for other types of
hrHPV plus HPV66. With respect to cytology, 57% of
cases and 38% of controls showed ASCUS+ (p = 0.004)
(Table 1).
The S5 classifier showed a highly significant increase
proportional to the severity of lesions (Cuzick test for
trend, p < 0.0001). Median methylation was 1.3 in histo-
pathologically negative samples (NEG), 1.7 in CIN1, 4.4
in CIN2, 6.5 in CIN3, and 19.2 in cervical cancer (CC)
(Additional file 2). Figure 2 shows the distribution of the
S5 classifier by histopathological diagnosis. The Mann-
Whitney U test revealed highly significant methylation
differences in the following pairwise comparisons: NEG
vs CIN2 (p = 0.01), NEG vs. CIN3 (p < 0.001), NEG vs CC
(p < 0.001), CIN1 vs CIN2 (p = 0.03), CIN1 vs. CIN3
(p < 0.001), CIN1 vs CC (p = 0.004), CIN2 vs CC (p =
0.007), and CIN3 vs CC (p = 0.02).
ROC analysis of the S5 classifier for detecting CIN2+
and CIN3+ gave areas under the curve (AUC) of 0.75
(95% CI 0.69–0.82) and 0.81 (95% CI 0.74–0.89) respect-
ively (Fig. 3). A new S5 cutoff value of 3.7 was selected for
better discriminating CIN2+ lesions from <CIN2 diagno-
ses in our already-triaged Mexican women with abnormal
cytology and/or HPV16/18 infection (Fig. 3). This cutoff
yielded a relative sensitivity and specificity of 62.0% (95%
CI 50.4–72.7) and 73.0% (95% CI 66.9–78.5) respectively
for CIN2+ (Table 2). The same cutoff for discriminating
CIN3+ from <CIN3 produced a sensitivity of 70.3% (95%
CI 56.7–81.8) and a specificity of 76.6% (95% CI 70.7–
81.9). In addition, we calculated the performance of the S5
classifier with a cutoff of 0.8 which was previously vali-
dated in the UK and Canadian screening populations. We
observed a better sensitivity for CIN2+ of 86.1% (95% CI
76.5–92.8) (p = 0.0005), but a worse specificity of 40.1%
(95% CI 33.8–46.6) (p < 0.0001) at the 0.8 S5 cutoff.
Of the 316 triage-positive samples, 218 were positive
for HPV16/18 and 134 were ASCUS+ (32 were HSIL).
The unadjusted sensitivity of HPV16/18 genotyping
for detecting CIN2+ was 63.3% (95% CI 51.7–73.9%),
with a specificity of 29.1% (95% CI 23.4–35.3, Table
2). Cytology alone with a cutoff of ASCUS+ had an
Fig. 1 Consort diagram of FRIDA nested case-control triage study showing the numbers of women in each step. Triage positive women included
HPV16/18 positive (<ASCUS) (n = 508), ASCUS+ (HPV16/18 negative) (n = 277), and HPV16/18 positive and ASCUS+ (n = 78). *Prior to July 2015,
672 out of 863 triage-positive women attended the colposcopy evaluation. Then, 561 women out of 672 who underwent colposcopy had
histology results recorded from April 2013 to the time of the study cutoff date on July 15. These 561 women are represented in our sampling
frame, from which we selected all the CIN2+ cases (79) and a random selection of three controls per case matched by age (1 CIN1 and 2 NEG). In
total, 316 participants were included in our methylation analysis: 79 CIN2+ cases, 79 CIN1, and 158 NEG. The cases included all the CIN2+
detected until July 2015. The three controls per case were randomly selected and matched by age from women with histological diagnoses of
CIN1 or less. The remaining 245 triage-positive women with histology results of CIN1 and negative would have been controls but were not
selected by the sampling method as we already had adequate power for the study. Abbreviations: hrHPV, high-risk human papillomavirus;
HPV16/18, human papillomavirus type 16 or type 18; ASCUS+, atypical squamous cells of undetermined significance or worse; NEG, histologically
negative; CIN, cervical intraepithelial neoplasia (of grades 1, 2, and 3)
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unadjusted sensitivity of 57.0 (95% CI 45.3–68.1) and
an unadjusted specificity of 62.4% (95% CI 55.9–68.8),
while cytology with a cutoff of HSIL+ had an un-
adjusted sensitivity and specificity of 27.8 (95% CI
18.3–39.1) and 95.8% (95% CI 92.8–98.0) respectively.
We investigated the positivity of different triage tests
for NEG, CIN1, CIN2, CIN3, and CC histopathological
diagnoses (Table 3). In the context of cervical cancer
screening in Mexico, a greater specificity would reduce
the number of women called for colposcopy (Table 3).
For example, HPV16/18 genotyping was positive in
72.2% of histologically negative women as opposed to
27.2% positive with S5 classifier at a cutoff of 3.7. All
three cancers were identified by HPV16/18 detection
and by the S5 classifier, but all were missed by cytology.
We subsequently explored the clinical utility of the S5
methylation classifier as a second or reflex triage test
(Fig. 4). The women in our study had increased risk of
CIN2+ whether they were positive for either or both
ASCUS and HPV16/18; therefore, we defined three risk
groups of women based on the outcomes of the latter
two tests. The first group consisted of HPV16/18-posi-
tive and ASCUS-positive women. We consider that these
women should be referred to colposcopy based on the
first triage alone. A second group represented a triage
discrepancy consisting of women negative for HPV16/18
but positive for an ASCUS+ result. In our study, these
women were also called for colposcopy, but in retro-
spect, some of them were considered to have gone un-
necessarily. The use of S5 methylation as a second triage
test in this group would have reduced colposcopy refer-
ral by 50% for a CIN2+ endpoint (p = 0.0000) or 43% for
a CIN3+ endpoint (p = 0.0000). In the third group,
women were HPV16/18 positive but had normal cy-
tology. All these women were also called for colposcopy.
Here again, the use of S5 methylation would have re-
duced colposcopy referral by 30% (CIN2+ endpoint, p =
0.0000) (Fig. 4a) or 28% (CIN3+ endpoint, p = 0.0000)
(Fig. 4b). In both groups 2 and 3, the sensitivity of S5 as
the second triage test was statistically no different than
in a scenario where all women were sent to colposcopy
(Table 3 and Fig. 4). This means that using S5 as a reflex
triage test would reduce the number of women unneces-
sarily sent to colposcopy by 30 to 50% while maintaining
the same sensitivity to detect CIN2+ (or CIN3+) as a tri-
age based on a combination of HPV16/18 and cytology.
Table 1 hrHPV type-specific prevalence and cytological evaluation in cases and controls
Controls (NEG/CIN1)
n = 237
Cases (CIN2+)
n = 79
Number Percent Number Percent p value^ OR (95% CI)
hrHPV positivity*
HPV 16+ 111 46.8 48 60.8 0.038 1.8 (1.05–2.94)
HPV 33+ 8 3.4 3 3.8 1.000 1.1 (0.32–4.04)
HPV 31+ 28 11.8 10 12.7 0.843 1.1 (0.51–2.31)
HPV 18+ 47 19.8 1 1.3 0.000 0.1 (0.0–0.30)
Other hrHPV+** 43 18.1 17 21.5 0.511 1.0 (0.60–1.67)
Cytological evaluation
Normal 148 62.5 34 43.0 0.004 0.5 (0.27–0.76)
ASCUS+ 89 38.0 45 57.0 0.004 2.2 (1.32–3.68)
LSIL+ 74 31.2 41 51.9 0.001 2.4 (1.42–3.99)
HSIL+ 10 4.2 22 27.9 0.000 8.8 (3.98–19.3)
HPV and cytology
HPV16/18+ and ASCUS+a 24 10.3 16 20.3 0.030 2.3 (1.14–4.47)
HPV16/18+ and LSIL+b 17 7.2 14 17.7 0.014 2.8 (1.32–5.89)
HPV16/18+ and HSIL+c 5 2.1 5 6.3 0.128 3.1 (0.94–10.4)
HPV16/18+ and normald 148 62.5 34 43.0 0.004 0.5 (0.27–0.76)
HPV16/18− and ASCUS+e 65 27.4 29 36.7 0.121 1.5 (0.90–2.62)
ASCUS+ atypical squamous cells of undetermined significance or worse, HSIL+ high-grade squamous intraepithelial lesion or worse, LSIL+ low-grade squamous
intraepithelial lesion or worse, NEG histologically negative, CIN cervical intraepithelial neoplasia (of grades 1, 2, and 3)
*Ranking of hrHPV genotypes according to the positive predictive values for CIN2+ (Cuzick, 2016)
**Other hrHPV: HPV35, 39, 45, 51, 52, 56, 58, 59, or 68 and HPV66 (a presumptive low-risk type)
^p value of two-sided Fisher´s exact test to evaluate differences in hrHPV prevalence as well as cytology results between cases and controls
aIncludes HPV16/18+ and ASCUS, LSIL, HSIL, and cervical cancer. bIncludes HPV16/18+ and LSIL, HSIL, and cervical cancer. cIncludes HPV16/18+ and HSIL and
cervical cancer. dIncludes HPV16/18+ and normal cytology. eIncludes HPV16/18− and ASCUS, LSIL, HSIL, and cervical cancer. Categories a, b, and c are not
mutually exclusive
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Discussion
There is increasing evidence that cervical precancer
arises primarily from persistent hrHPV infection in con-
cert with reasonably well-understood abnormal epigen-
etic events. Host cells can respond to HPV infection
with a cascade of defense mechanisms such as induction
of interferon pathways, increased APOBEC-related DNA
editing, and increased methylation. Such activity can get
out of control and result in genome integrity problems,
which in pluripotent cells have dangerous effects. Since
the defense mechanisms are unable to subdue persistent
HPV infections in a timely manner, they may instead
participate in concert with continued over-expression of
the HPV E6 and E7 oncoproteins as drivers towards
cancer [28, 29, 41].
DNA methylation is a particularly tractable feature of
the epigenetic machinery because patterns of CpG
methylation are measurable as signatures and are stably
retained during mitotic cell division. This feature en-
couraged us to explore the clinical utility of the S5
DNA methylation classifier as a triage test in our study
of women with abnormal cytology and/or HPV16 and
HPV18 infections. An important finding of our study is
that the S5 classifier, at a modified cutoff of 3.7 (more
favorable for women already triaged by cytology or
HPV16/18 testing), was able to detect 62.0% of CIN2+,
70.3% of CIN3+, and all cancers in our study. In par-
ticular, S5 was able to provide important additional in-
formation for women with discrepant results between
HPV16/18 and cytology. We believe that a combined
triage approach that is cost-effective, with good specifi-
city and a sensitivity of greater than 60% for CIN2/3, is
generally safe for use in Mexico and also in women
residing in low- and middle-income countries (LMIC),
because of two important considerations: firstly, it is
not crucial to detect all precancers in the first screen
because most of these lesions regress or progress quite
slowly; however, cancers are not reversible, and in our
study, all cancers were detected by S5. Furthermore, in
two other studies, S5 was also shown to have a ~ 100%
sensitivity for cervical cancer [28, 32]. Secondly, add-
itional intensive follow-up of all triage test-negative
women is a standard recommendation, meaning that
most if not all cancers in development can be caught at
an early stage when cure rates are high (> 95%) as long
as the women alerted to follow-up adhere to recom-
mendations. A pressing priority in Mexico and indeed
in most LMIC is to not overwhelm colposcopy clinics.
Fig. 2 Comparison of S5 methylation classifier in histologically negative (NEG), CIN1, CIN2, CIN3, and cervical cancer cases (CC). The S5 classifier
was significantly different between the following group comparisons: NEG vs CIN2 (p = 0.01), NEG vs CIN3 (p < 0.001), NEG vs CC (p < 0.001), CIN1
vs CIN2 (p = 0.03), CIN1 vs CIN3 (p < 0.001), CIN1 vs CC (p = 0.004), CIN2 vs CC (p = 0.007), and CIN3 vs CC (p = 0.02). Other comparisons were not
significant (NEG vs CIN1 and CIN2 vs CIN3). Abbreviations: NEG, histologically negative; CIN, cervical intraepithelial neoplasia (of grades 1, 2, and
3); CC, cervical cancer. The top of box represents the upper quartile (p75), bottom the lower quartile (p25), and the line the median (p50). The
upper whisker extends to the largest point of the inter-quartile range from the upper quartile. The lower whisker extends to the smallest point of
the inter-quartile range from the lower quartile. The outliers are plotted as individual points for each lesion grade. The Cuzick test for trend was
highly significant (p < 0.001)
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A workload increase in these clinics could lead to in-
creasingly poor outcomes and potentially to increases
in cancer due to hurried and inadequate assessment of
women, who may be given false-negative diagnoses or
who may be lost to follow-up [42, 43]. Our results sup-
port a proposal to create enhanced risk scores that
combine methylation of target genes with current
cytology and HPV16/18 triage testing options for
hrHPV screen-positive women.
Another major finding of our study is confirmation of
the diagnostic utility of S5 seen in two earlier validation
studies, a large screening study in the UK and a random-
ized control trial in Canada [28, 32]. In the hrHPV-
based screening population from the UK, using a cutoff
of 0.8 for S5, the AUC obtained for CIN2+ was 0.78
(95% CI 0.69–0.88), similar to the AUC of 0.75 (95% CI
0.69–0.8) seen in our FRIDA population. The 0.8 cutoff
used in the UK population gave a higher sensitivity but a
lower triage specificity compared with our S5 cutoff of
3.7. In previous studies of S5 performance, the sensitivity
for cancer at the suggested triage cutoff of 0.8 was 100%.
In our study, we showed that even at a cutoff of 3.7, all
cancers were detected. Similar data have also been
shown in other studies [28, 32], which indicates that few
if any cancers would be missed when employing DNA
methylation signatures for triage, even with a rather high
S5 cutoff of 3.7 or perhaps higher.
Most lesions resulting from an infection with hrHPV
eventually regress and only a very small number (< 5%)
ever go on to invasive cancer in the absence of screening
[3, 6]. To decrease costs and to avoid a large amount of
unnecessary treatment, it is of great importance to identify
hrHPV-positive women who are most likely to develop
truly precancerous high grade CIN and to clearly separate
them from women with CIN2 and CIN3 who will not
develop cervical cancer at all or at least not over several
decades [9, 14, 44]. Previous studies have proposed classi-
fiers based on the methylation of HPV types (classifiers
S1, S2 [22], and S4 [30]) and or human genes [40].
The S5 classifier was positive in 27% of our selected
controls, but it is worthwhile to recall that these were
Table 2 Performance of the S5 methylation classifier, cytology, and HPV16/18 genotyping for detecting CIN2+ and CIN3+
Sensitivity
(95% CI)
Specificity
(95% CI)
Unadjusted PPV
(95% CI)
Adjusted PPV*
(95% CI)
Unadjusted NPV
(95% CI)
OR (95% CI)
S5 cutoff 3.7
CIN2+ 62.0 (50.4–72.7) 73.0 (66.9–78.5) 43.4 (34.0–53.0) 20.3 (16.7–23.9) 85.2 (79.6–89.8) 4.20 (2.59–7.54)
CIN3+ 70.3 (56.7–81.8) 76.6 (70.7–81.9) 45.0 (35.0–55.3) 18.0 (14.3–21.7) 90.5 (85.0–94.2) 7.75 (4.21–14.3)
S5 cutoff 0.8
CIN2+ 86.1 (76.5–92.8) 40.1 (33.8–46.6) 32.4 (26.1–39.2) 13.8 (11.5–16.0) 89.6 (82.2–94.7) 4.14 (2.10–8.14)
CIN3+ 92.5 (91.8–97.9) 38.8 (32.9–45) 23.3 (17.8–29.6) 9.9 (8.0–11.9) 96.2 (90.6–99.0) 7.76 (3.83–21.2)
HPV16/18 and cytology for CIN2+
HPV16/18+ 63.3 (51.7–73.9) 29.1 (23.4–35.3) 22.9 (17.5–29.1) 9.0 (7.2–10.9) 70.4 (60.3–79.2) 0.71 (0.42–1.21)
ASCUS+ 57.0 (45.3–68.1) 62.4 (55.9–68.6) 33.6 (25.7–42.2) 14.4 (11.5–17.3) 81.3 (74.9–86.7) 2.20 (1.3–3.7)
LSIL+ 51.9 (40.4–63.3) 68.8 (62.5–74.6) 35.7 (26.9–45.1) 15.6 (12.3–18.8) 81.1 (75.0–86.3) 2.38 (1.42–3.99)
HSIL+ 27.8 (18.3–39.1) 95.8 (92.8–98.0) 68.8 (50.0–83.9) 42.3 (34.0–50.6) 79.9 (74.8–84.4) 8.70 (3.9–19.2)
ASCUS+ atypical squamous cells of undetermined significance or worse, HSIL+ high-grade squamous intraepithelial lesion or worse, LSIL+ low-grade squamous
intraepithelial lesion or worse, NEG histologically negative, CIN cervical intraepithelial neoplasia (of grades 1, 2, and 3).
*Adjusted PPV = (Sn × Pr)/((Sn × Pr) + (1 − Sp ) × (1 − Pr)), where Sn is sensitivity, Sp is specificity, and Pr is the CIN2+ or CIN3+ screening prevalence in the FRIDA
population-based study (10% and 6.8% respectively)
Fig. 3 Receiver operator characteristic (ROC) and area under the
curve (AUC) of S5 methylation for detecting CIN2+ or CIN3+. The
blue diamond denotes the sensitivity and specificity of S5 at a cutoff
of 3.7 for CIN2+. The red circle denotes the sensitivity and specificity
at the S5 cutoff of 0.8 predefined for use in the UK for CIN2+. The
cutoff for cytology alone was ASCUS+. Abbreviations: ASCUS+,
atypical squamous cells of undetermined significance or worse
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women with either HPV16/18 infection or an abnormal
cytology who were not subsequently diagnosed with
CIN2+. Previous studies have observed that DNA
methylation can predict the persistence of HPV infection
of different viral types [22–24, 45]. Thus, it can be
suggested that women, for whom a first colposcopy
evaluation detected no significant lesions, could be
carefully evaluated in follow-up visits to document
quantitative changes in methylation consistent with the
clearance or progression of disease.
Our results are applicable to methylation triage of
women who are discrepantly positive for HPV16/18
and/or cytology ASCUS+; however, we were not able to
assess if S5 could be used for triage of all hrHPV-
positive women. The use of S5 could reduce colposcopy
rates by up to 50% without a loss of sensitivity to detect
cancer, which would be a big saving for any LMIC, not
just because of lower financial costs but because of over-
all lower clinical burden. Furthermore, as shown by our
results on women with concordant positive results for
both HPV16/18 and cytology, the S5 test may also be
useful for women who had a normal colposcopy. In this
situation, a negative methylation result (S5 = 0) would
provide reassurance against missed disease, especially if
there is a high risk of loss to follow-up. The new cutoff
proposed and different values of high methylation need
to be validated in the setting of LMIC to estimate the
clinical utility in populations with a similar context of
income and disease prevention strategies to estimate the
risk of cervical cancer.
The use of our particular triage population underes-
timates the number of potential cases of CIN2+ attrib-
utable to non-HPV16/18 hrHPV types; however, many
of these women may be identified on follow-up. We
consider that an introduction of S5 DNA methylation
testing for routine use in self-validated expert clinical
diagnostics laboratories is a reasonable course and, in
some cases, could be undertaken quite quickly, being
advantageous to further triage of women with HPV16/
18 and/or abnormal cytology results. Successful imple-
mentation would allow colposcopy clinics to see only
the highest-risk women and thereby attain higher
quality and better manage overtreatment. Excessive
burdening of clinical services and overtreatment of
women are negative features of medical practice today
due to an increasing flood of new women identified in
expanded national HPV screening programs [46].
Based on practical experience from our laboratory, the
cost of an S5 DNA methylation test is not more than a
routine HPV screening and reflex genotyping. Thus,
the S5 test could be applied to a minority of the
women, and incremental costs could be balanced
against the expected 30 to 50% reduction in colpos-
copy referral costs. Also, of note, the three cancers
were detected by both HPV16/18 testing and the S5
test, but all of them were missed by cytology (Table 3).
If confirmed by larger studies, this observation may
allow for a generalized rapid reduction in cervical can-
cer in LMIC, which have been particularly poorly
served by cytology screening over the past 50 years.
Expected large-scale cervical cancer incidence reduc-
tions from implementation of the prophylactic HPV
vaccine are still many decades away, and it is prudent
to take more preventative actions in the meantime.
Our study has some important strengths including that it
is the largest screening multi-triage study of cervical cancer
in an LMIC. All primary clinical and laboratory procedures
(screening, triage, colposcopy, and histopathological assess-
ments) were done completely within Mexico. We selected
all available cases and three matching controls, the latter
specimens being selected at the same time and diagnosed
in the same corresponding months as the cases. The accur-
acy of the colposcopic evaluation in FRIDA was very high
and was not typical of Mexico, LMICs, or even developed
countries such as the USA and Europe because it was per-
formed by specially trained experts and also did not depend
only on the visual expertise of the colposcopists. At least
one biopsy was taken from each quadrant of the cervix in
all women to reduce verification bias. Additionally, the
histopathological evaluation and diagnostic confirmation of
the biopsies and/or endocervical samples of all women
included in our study were reviewed by a panel of
Table 3 Positivity of different triage tests for histologically negative (NEG), CIN1, CIN2, CIN3, and CC
NEG (n = 158) % (95% CI) CIN1 (n = 79)
% (95% CI)
CIN2 (n = 26)
% (95% CI)
CIN3 (n = 50)
% (95% CI)
CC (n = 3)
% (95% CI)
HPV16/18+ 72.2 (64.6–78.6) 68.4 (57.1–77.8) 65.4 (44.3–81.8) 60.0 (45.5–72.9) 100
ASCUS+ 30.4 (23.6–38.1) 51.9 (40.7–62.9) 61.5 (40.7–78.9) 58.0 (43.6–71.2) 0
LSIL+ 25.9 (19.7–33.4) 41.8 (31.2–53.1) 61.5 (40.7–78.9) 50.0 (36.0–64.0) 0
HSIL+ 3.2 (1.3–7.4) 6.3 (2.6–14.6) 19.2 (7.7–40.4) 34.0 (21.9–48.6) 0
S5 at 3.7 cutoff 27.2 (20.8–34.8) 26.6 (17.9–37.6) 50.0 (30.5–69.5) 66.0 (51.4–78.1) 100
S5 at 0.8 cutoff 57.6 (49.7–65.4) 64.6 (53.2–74.5) 73.1 (51.7–87.3) 92.0 (79.9–97.1) 100
ASCUS+ atypical squamous cells of undetermined significance or worse, HSIL+ high-grade squamous intraepithelial lesion or worse, LSIL+ low-grade squamous
intraepithelial lesion or worse, NEG histologically negative, CIN cervical intraepithelial neoplasia (of grades 1, 2, and 3), CC cervical cancer
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pathologists, including an international expert. Moreover,
all methylation measurements were done by blinded
laboratory staff, including a scientist from Mexico (RH),
with the aim of avoiding differential information bias.
Conclusions
The S5 methylation classifier provides good sensitivity,
specificity, and positive predictive value as a triage test
for colposcopy referral in Mexican women with HPV16/
18+ and/or ASCUS+, especially if CIN2/3 with low
methylation do not progress, which is a subject of on-
going studies. We believe that our study and the existing
literature on this topic support the use of methylation
biomarkers in the triage of hrHPV-positive women
within cervical cancer prevention programs in both
highly developed settings and in LMICs. S5 methylation
triage can reduce the numbers of needed colposcopies
by an additional 30 to 50% as compared to triage by cy-
tology and HPV16/18 genotyping while detecting all
cancers. Such steps would greatly reduce existing costs
and allow healthcare staff to better focus on the women
at real risk of cervical cancer.
Methods
Study population
We performed a nested case-control analysis in a
subset of hrHPV-positive women participating in the
Fig. 4 Benefit of using the S5 classifier as a second triage test for colposcopy referral for a) CIN2+ and b) CIN3+ endpoints. S5 helped reduce
unnecessary colposcopy referrals in both the “HPV16/18 neg, ASCUS+” and “HPV16/18 pos, normal cytology” groups. Under the current Mexican
algorithm, all HPV16/18 positive and/or ASCUS positive are referred to colposcopy, but we propose to use S5 as second triage test for the
discrepant triage groups (“HPV16/18 neg, ASCUS+” and “HPV16/18 pos, normal cytology”) which then decreases the false-positive rate. We
therefore defined the following hypothesis to test S5 benefits. In group 1, women were HPV16/18 positive and ASCUS positive and must be
referred to colposcopy without any additional triage procedure. In group 2, women were HPV16/18 negative and ASCUS positive and were called
for colposcopy, but if we had used S5 methylation as a second triage test, it would have reduced by 50% (CIN2 endpoint) or 43% (CIN3
endpoint) the number of false positives referred to colposcopy. Using S5 methylation as a second triage for women in group 3, who were
HPV16/18 positive with normal cytology, would have reduced unnecessary colposcopy referrals by 30% in CIN2+ and 28% in
CIN3+. Abbreviations: ASCUS+, atypical squamous cells of undetermined significance or worse; CIN, cervical intraepithelial neoplasia (of grades 1,
2, and 3). The frequency shows the absolute number of women in each group
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FRIDA screening study, all of whom underwent
colposcopy (Fig. 1). Details of the study methods have
been described previously [47]. Briefly, FRIDA is a
population-based study that recruited 36,212 women
from a target population of close to 60,000 women
aged 30–64 years, between April 2013 and February
2016. Women were users of public health services,
who attended the Cervical Cancer Screening Program
in 100 primary health care facilities in the state of
Tlaxcala, Mexico. The main aim of FRIDA was to
evaluate the performance of different triage tests for
hrHPV-positive women. Women who were pregnant
at the time of recruitment or had a prior hysterectomy
were excluded. Informed consent was required for
women to participate in the study. The population
sampling for this nested case-control study was se-
lected from a pool of women attending colposcopy be-
cause they were either singly positive or positive for
both cytology and HPV16/18 between April 2013 and
July 2015, when 29,759 women had been enrolled.
Women who were infected by HPV types other than
HPV16 or HPV18 who did not have cytological abnor-
malities were excluded for this analysis.
FRIDA is registered in ClinicalTrials.gov, number
NCT02510027, and was approved by the Institutional
Review Boards (IRBs) of the participating institutions:
National Public Health Institute (INSP) [1094], Tlaxcala
State Ministry of Health [SS.DECI-OI-13/12], and the
Mexican regulatory agency COFEPRIS [CAS/OR/01/
CAS/123300410C0044-3578/2012].
Selection of cases and controls
The nested case-control triage study considered hrHPV-
positive women who attended for colposcopy as a result
of a positive test by HPV16/18 (n = 586) or a cytological
diagnosis of atypical squamous cells of undetermined
significance or worse (ASCUS+) (n = 277). HPV testing
for 13 high-risk HPV types and HPV66, followed by
HPV16/18 genotyping, were performed by the Cobas®
4800 DNA test (Roche, Pleasanton, CA, USA) as de-
scribed below. Endocervical curettage was performed for
all women referred for colposcopic evaluation, during
which one biopsy was also collected from what the col-
poscopist suspected to be the most abnormal zone of
each quadrant. Evaluation of all histological samples was
conducted by a standardized panel of pathologists. If
two pathologists agreed in their diagnosis, this was the
final conclusion. If the diagnoses were discordant, an
additional interpretation was made by a third expert
pathologist. In this case, the assigned diagnosis was
based on the agreement of two out of three pathologists
or, if totally discordant, on the result given by the expert
pathologist.
Cases and controls were selected based on the histological
status. All women diagnosed with CIN2, CIN3, or invasive
cervical cancer were defined as cases. For each case
identified, we selected three age-matched controls:
one control diagnosed with low-grade cervical intra-
epithelial neoplasia (CIN1) and two controls with no
evidence of any cervical intraepithelial lesion (NEG).
Controls were selected randomly within a 2-month
time frame of the case diagnosis.
Collection and shipment of cervical samples
DNA methylation assays were performed on an aliquot
of cervical samples obtained from the screening visit. In
this visit, a first cervical sample was collected in a Sure-
Path (Becton Dickinson, Sparks, MD, USA) vial and used
for the cytology procedure. Cervical samples for HPV
and methylation testing were collected as a second sam-
ple and placed in a vial containing ThinPrep® preserva-
tive (Hologic, Inc., Bedford, MA). Both samples were
collected using a Cervex-Brush® (Rovers®) in the screen-
ing visit. The samples were temporarily stored at room
temperature at the health center until they were
delivered to HPV laboratory facilities where aliquots
were made and kept frozen at − 70 °C. The samples
were shipped on dry ice to the Molecular Epide-
miology Laboratory of the Wolfson Institute of Pre-
ventive Medicine (Queen Mary University of London,
UK) for analysis.
HPV detection
The samples were tested for hrHPV using the Cobas®
4800 HPV test (Roche Molecular Systems, Pleasanton,
CA). This system extracted DNA and amplified by PCR
using specific primers to human beta globin and hrHPV.
HPV16 and HPV18 are identified individually and other
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, and 68) were detected as a pool.
Since the Cobas® assay does not give individual typing
of HPV31 and HPV33, the prevalence of these two HPV
types was estimated by the detection of amplicons spe-
cific for these two HPV types in the PCR reactions
(HPV31L1 and HPV33L2) leading up to the methylation
assays.
Methylation assays
For methylation assays, the DNA was extracted from cer-
vical samples using a QIAamp mini kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions. Subse-
quently, the DNA was quantified by UV absorption using a
NanoDrop spectrophotometer. An aliquot of 500 ng of
DNA underwent bisulfite conversion in which unmethy-
lated cytosines were converted to uracil using the EZ DNA
methylation kit (Zymo Research, Irvine, CA) following the
manufacturer’s instructions. This kit is designed to reduce
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degradation and minimize the loss of DNA. The DNA was
eluted in 20 μl of Elution Buffer.
After DNA conversion, the PyroMark PCR Kit
(Qiagen) was used to amplify the following CpG sites:
HPV16 L1 (6367 and 6389), HPV16 L2 (4238, 4247,
4259, 4268, and 4275), HPV18 L2 (4256, 4261, 4265,
4269, 4275, and 4282), HPV31 L1 (6352, 6364), HPV33
L2 (5557, 5560, 5566, and 5572), and human gene
EPB41L3 (425, 427, and 438). PCR products were pyro-
sequenced using a PyroMark Q96 ID instrument
(Qiagen), and the proportions of cytosine and thymine
were quantified for each CpG site. The laboratory was
blinded to the cytology and histology results. The pro-
cedures and quality control of these experiments have
been reported previously [23, 27].
Data analysis
Socio-demographic, lifestyle, and sexual behavior of
cases and controls were summarized as means or pro-
portions. We computed the specific prevalence of HPV
types (16, 18, 31, and 33) within our study population.
Differences across all variables between cases and con-
trols were tested using a two-sided, difference of propor-
tions by a binomial test or difference of medians by a
Mann-Whitney U test. Our primary goal was to assess
the clinical performance of the S5 classifier. This score
was calculated using the average methylation values of
all the target regions using the following standardized
equation [31]:
S5 = EPB41L3*(30.9) +HPV16L1.3*(13.7) +
HPV16L2*(4.3) +HPV18L2*(8.4) +HPV31L1*(22.4) +
HPV33L2*(20.3)
We created boxplots to illustrate the distribution of
the S5 classifier according to the histopathological diag-
nosis of the lesions (NEG, CIN1, CIN2, CIN3, and inva-
sive cervical cancer (CC)). We used the Mann-Whitney
U test for comparing S5 differences between different
disease categories and the Cuzick test for trend to deter-
mine if methylation increased significantly as a function
of greater histology result.
In order to maximize the sensitivity and specificity of
the S5 score after the triage test (HPV16/18 and cytology)
we calculated receiver operating characteristic curves
(ROC) to estimate areas under the curve (AUC) and to
obtain a new cutoff value that best discriminated hrHPV-
positive women with CIN2+ (cases) from controls who
did not have histologic abnormalities, in order to
maximize the sum of sensitivity and specificity of the S5
score among our already-triaged samples. Based on this
new cutoff value, we set a disease endpoint of CIN2+ to
estimate sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV); the PPVs
were also adjusted for CIN2+ and CIN3+ prevalence
(10.0% and 6.8% respectively) using the following formula:
PPV = (Sn × Pr)/((Sn × Pr) + (1 − Sp) × (1 − Pr)), where Sn
is sensitivity, Sp is specificity, and Pr is the CIN2+ or
CIN3+ prevalence. A ROC curve was also computed for
CIN3+ versus NEG/CIN1. We compared the performance
of S5 with HPV16/18 detection and cytology to identify
CIN2+ using crude estimators because it was not possible
to adjust for the bias created by not referring all hrHPV
positive women to colposcopy; in effect, HPV16/18 diag-
nostic performance was assessed versus a comparator
composed of HPV16/18 plus cytology ASCUS+; similarly,
ASCUS+ cytology performance was compared to the same
composite comparator. A second analysis was done using
the established 0.8 cutoff validated earlier in a UK
screening population for detection of CIN2+ and CIN3+.
All p values were estimated as two sided, with a confi-
dence interval of 95%. Statistical analyses were performed
using STATA software v.14.0 (StataCorp LP, College
Station, TX).
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